Aug 02, 2021 06:01 PM (GMT+8)
The announcement of the essence pharmaceuticals is to sell the 24.87% stake of Jiangsu Wan Long Pharmaceutical Co., Ltd. through the public resources trading platform of Nantong, and the listing price is no less than 69 million 398 thousand and 700 yuan. The original intention of the company's investment in wanlao pharmaceutical is to cut into the lipid-lowering drug statin API and its pharmaceutical intermediate industry. However, because the company fails to effectively cut into the downstream of the statin industry, it plans to sell all the equity of wanlao pharmaceutical.
This text is a result of machine translation.